IB Net Payout Yields Model

Invest like me - only at Covestor.com

Nikola: Making Progress, But Lacks Capital

By -

 

  • Nikola has started making real progress towards becoming a legitimate BEV manufacturer.
  • The company forecast delivering up to 100 units by year end after starting trial production this month.
  • The company needs more capital and normal production delays are likely to disappoint shareholders.
  • Investors should wait for a dip to buy the stock as a 9x EV/S target for 2025 is still expensive for the risk.
  • Looking for more investing ideas like this one? Get them exclusively at Out Fox The Street. Learn More »
As someone ultra bearish on Nikola (NKLA) after the company went public via a SPAC to an irrational valuation, my view is now more neutral on the stock. The BEV company has made substantial progress towards becoming a legitimate manufacturer of trucks. Ultimately though, my investment thesis is neutral on the stock as the current price is still over 9x 2025 sales targets.

Read the full article on Seeking Alpha. 

Disclosure: No position mentioned. Please read the disclaimer page for more details. 


Update - July 29

No surprise the former CEO is being charged with fraud. The surprise is that the stock is down 11% on this news possibly providing a part of the bottoming process. The current Nikola is nothing like the old Nikola under Trevor Milton. 

Finviz Chart

  • Nikola (NASDAQ:NKLA) falls after company founder Trevor Milton is charged by the U.S. Attorney's Office in Manhattan with three counts of making false and misleading statements to investors.
  • The charging document alleges Milton mislead investors on "nearly all aspects" of the business.

Update - June 14

Interesting deal to raise some capital here. Nikola needs far more than $300 million so this deal is only a start keeping us on the sidelines for more capital raises. 

-Shares of Nikola are down in premarket trading Monday after the company strikes a deal to sell up to $300 million worth of stock to Tumim Stone Capital.

The stock continues making a base with a retest of $15 or below likely. 

Finviz Chart

Popular posts from this blog

Occidental: Still Producing Too Much Oil

By -
Image
Though oil continues plunging, the oil giants continue producing more. For Q4, Occidental Petroleum (OXY) had roughly flat production. The worst part is that OXY plans to grow production by 2% to 4% in 2016. The stock has held up somewhat strong, but the inability to turn off the spigot remains troubling. Disclosure: No positions mentioned. Please review the disclaimer page for more details. 
Read more

ChargePoint: Low Quality Beat

By -
Image
  ChargePoint beat FQ2'22 revenue estimates, but the losses are mounting. The company guided up FY22 numbers partly due to acquisitions. The stock still trades at an estimated 21x FY23 number leaving limited upside for the stock and reinforcing why venture funds sold 13.8 million shares. Looking for a portfolio of ideas like this one? Members of Out Fox The Street get exclusive access to our model portfolio.  Learn More » After  solid FQ2'22 earnings ,  ChargePoint Holdings  ( CHPT ) has seen a nice bump in the stock. Now investors have to confront the valuation divide and deal with the past insider sales likely leading to future sales on any stock rallies. My  investment thesis  remains very Bearish on the EV charging station stock on any rallies into the mid-$20s. Read the full article on Seeking Alpha.  Disclosure: No position mentioned. Please review the disclaimer page for more details.  Update - Sept. 8 Be cautious when analysts struggle to make the bullish case on expen
Read more

Aurora Cannabis: Deal Or No Deal

By -
Aurora Cannabis was left out of the major deal making in 2018. The cannabis company updated FQ2 guidance to revenues of $50 to $55 million with a continued focus on pure production growth. The stock is down as the market is becoming less impressed with commodity farming operations due to the prime Oregon example. The stock is below key resistance at $5.40 as medical cannabis patient totals failed to impress. As the end of 2018 came and went,   Aurora Cannabis   ( ACB ) was a notable absentee from the deal making in the cannabis market. Just about all of the other major Canadian cannabis players got large investments or signed up powerful partnerships, but the related stocks didn't generally maintain rallies following the deals. Based on the early legalization data in Canada and Oregon, the best option for Aurora Cannabis might actually be selling production capacity while the Canadian market remains hot. Read the full article on Seeking Alpha.  Disclosure: No
Read more